NCT06828055

VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 280 (actual)
• Sponsor: Viking Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.

Conditions

• Weight Loss

Interventions

Type	Name	Description
DRUG	Placebo	Matching Placebo to VK2735
DRUG	VK2735	Active Treatment

Timeline

• Start date: 2024-12-18
• Primary completion: 2025-06-24
• Completion: 2025-08-15
• First posted: 2025-02-14
• Last updated: 2025-10-06

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study